BioXcel Therapeutics, Inc.

Proud to announce that Friso Postma, our VP of AI Drug Discovery, will be speaking on a panel at Boehringer Ingelheim and BioCT’s #AISummit to discuss innovative applications of AI across research and development. Join us! https://lu.ma/oijbjl9r #AI #ResearchandDevelopment

We have just announced our Q3 2024 earnings. Learn more.??https://bit.ly/3YQUaVj

We are pleased to have advanced our pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia. Learn more.?https://bit.ly/3AskPzB

We'll be reporting our third quarter 2024 financial results on November 14, 2024. Learn more. https://bit.ly/4fg5WQ0

We'll be reporting our third quarter 2024 financial results on November 14, 2024. Learn more. https://bit.ly/4fg5WQ0

Dusan Kostic, our Head of Medical Affairs, recently presented data on Igalmi? (dexmedetomidine sublingual film) in Boston.?https://bit.ly/3ZDVzg5 Thanks to #psychcongress2024 for the opportunity to participate in this important scientific forum.

Friso Postma, our VP of AI Drug Discovery, joined industry leaders to discuss Real Use of AI in Pharma: Today and in the Near Future. Thanks to?#BioFuture2024 for the opportunity to participate in this important discussion impacting our industry.

Friso Postma, our VP of AI Drug Discovery, will be participating in a thought-provoking panel at #BioFuture2024 on Oct. 30 at 11 a.m. He’ll be joining industry leaders to discuss Real Use of AI in Pharma: Today and in the Near Future. Register at?www.BioFuture.com! ?

We’re excited?to be participating at Psych Congress in Boston. We’ll be presenting data on Igalmi (dexmedetomidine sublingual film). Stop by poster 177 Oct. 31 & Nov. 1 from 1:30-3 p.m. to learn more.??https://bit.ly/3ZDVzg5

BioXcel Therapeutics will be presenting at ThinkEquity Conference. The presentation is set for Wednesday, October 30 at 2 p.m. ET.?https://bit.ly/3Ylw98x